KLOW
80mg
A quad-peptide research blend designed to cover the complete tissue repair cascade.A quad-peptide research blend designed to cover the complete tissue repair cascade. KPV resolves inflammation first — suppressing NF-κB to create the conditions for repair. GHK-Cu then activates collagen and extracellular matrix gene expression. BPC-157 builds the vascular supply through angiogenesis. TB-500 mobilizes cells into position via actin dynamics. Four independent mechanisms, one regenerative endpoint.
Four pathways.
One complete
protocol.
A quad-peptide research blend adding KPV’s NF-κB-mediated inflammation resolution upstream of GHK-Cu’s ECM gene activation, BPC-157’s angiogenesis, and TB-500’s cell mobilization — four complementary mechanisms covering the complete tissue repair cascade from inflammation gate to structural rebuild.
Getting et al. J Pharmacol Exp Ther 2003 · Pickart & Margolina 2018 · Sikiric et al. 2018 · Goldstein et al. 2012. All data from peer-reviewed literature. For Research Use Only — Not for Human Consumption.
Manufactured in US
US-formulated & filled
Endotoxin Tested
<0.05 EU/mL all 3 peptides
Independently Tested
Horizon Analytical · 6-panel COA
Same Day Shipping
Order by 3PM PST
KLOW blend components are supplied exclusively for qualified in vitro laboratory research. Not for human administration.
This product is a research-grade quad-peptide blend supplied under research use only (RUO) designation. KPV, GHK-Cu, BPC-157, and TB-500 are not approved by the FDA for any therapeutic indication. By purchasing, the buyer represents they are a qualified researcher using these compounds solely for lawful in vitro laboratory research. Not a drug, dietary supplement, food, or medical device. For Research Use Only — Not for Human Consumption.
Four peptides.
Four mechanisms.
Each compound in KLOW addresses a distinct but overlapping aspect of tissue regeneration. Their mechanisms are not redundant — they are additive and in several pathways, synergistic.
GHK-Cu
Glycyl-L-histidyl-L-lysine•Cu2+
ECM ArchitectA naturally occurring copper-bound tripeptide found in human plasma, saliva, and urine. Concentration declines with age. Acts as a master regulator of extracellular matrix biology — upregulating collagen synthesis, modulating metalloproteinase activity, and activating gene expression programs linked to tissue repair. Studied for its influence on 4,192 human genes in published genomics research.
4,192
Genes modulated
3 AA
Gly-His-Lys
TGF-β
Collagen pathway
Cu2+
Copper-mediated
BPC-157
Body Protection Compound — 15 AA
Vascular BuilderA 15-amino acid pentadecapeptide derived from a partial sequence of a naturally occurring protein in human gastric juice. Demonstrates remarkable stability under physiological conditions. The primary driver of angiogenesis in the blend — upregulating VEGFR2, activating FAK-paxillin signaling in endothelial migration, modulating nitric oxide, and promoting fibroblast organization across muscle, tendon, ligament, and gut tissue.
15 AA
Pentadecapeptide
VEGFR2
Angiogenesis
FAK
Cell migration
NO
eNOS modulation
TB-500
Thymosin Beta-4 Fragment — 43 AA
Cell MobilizerA synthetic peptide based on the active region of thymosin beta-4, a naturally occurring protein present in virtually all cells. Its primary mechanism is G-actin sequestration — binding monomeric G-actin in a 1:1 ratio to regulate actin polymerization, which controls cell motility, wound closure, and tissue remodeling. Also mobilizes endothelial progenitor cells and facilitates vascular remodeling in ischemic tissue models.
43 AA
Actin-binding motif
G-actin
1:1 sequestration
~4963
Daltons MW
EPC
Progenitor recruitment
Why these four
together.
Each peptide in KLOW targets a different stage and mechanism of the tissue repair cascade. Their pathways are distinct but converge on the same biological endpoint — making them additive rather than redundant. In preclinical models, specific peptide combinations engaged simultaneously produce effects that exceed those of any single component by activating multiple complementary repair mechanisms in parallel.
GHK-Cu — ECM Foundation
Activates TGF-β to upregulate type I and III collagen. Modulates metalloproteinases (MMP-1, MMP-2) to remodel the extracellular matrix. Promotes glycosaminoglycan synthesis. Operates at the level of gene expression — switching on the structural blueprint for tissue architecture. Most potent copper-binding peptide for collagen gene activation.
BPC-157 — Vascular Supply
Upregulates VEGFR2 to stimulate new capillary formation. Activates FAK-paxillin pathway for endothelial cell migration. Modulates eNOS and nitric oxide signaling. Protects cells from oxidative stress. Promotes fibroblast outgrowth and organization. Without adequate blood supply (angiogenesis), GHK-Cu’s collagen synthesis and TB-500’s cell migration cannot proceed. BPC-157 provides the vascular infrastructure.
TB-500 — Cell Mobilization
Sequesters G-actin to regulate cytoskeletal dynamics — enabling keratinocytes, fibroblasts, and endothelial cells to migrate into the wound site. Mobilizes endothelial progenitor cells from bone marrow. Complements BPC-157’s angiogenic signaling by physically moving cells to where the new vasculature is forming. In rodent wound models: 42–61% increased re-epithelialization with enhanced collagen deposition.
Pathway Convergence
Synergistic Regenerative Effect
GHK-Cu activates the structural genes → BPC-157 builds the vascular supply → TB-500 moves cells into position. Three stages, three peptides, one outcome: organized tissue repair with structural integrity, adequate perfusion, and populated cellular architecture.
Four orthogonal pathways,
one endpoint.
The four compounds share no primary receptor or signaling molecule — their mechanisms are orthogonal. This independence is what makes the combination research-relevant.
| Mechanism | KPV | GHK-Cu | BPC-157 | TB-500 |
|---|---|---|---|---|
| Anti-inflammatory | ✓ NF-κB primary | ✓ NF-κB support | ✓ Cytokine balance | ✓ Resolution |
| Primary mechanism | NF-κB / PepT1 | ILK / TGF-β | VEGFR2 / FAK / eNOS | G-actin sequestr. |
| Collagen synthesis | Enables via inflam. res. | ✓ Primary driver | ✓ Fibroblast support | Indirect |
| Angiogenesis | Indirect | ✓ VEGF upregulation | ✓ Primary driver | ✓ EPC mobilization |
| Cell migration | Indirect | ECM prep | ✓ Endothelial | ✓ Primary driver |
| Antioxidant | Indirect | ✓ SOD & catalase | ✓ Oxidative protect. | Indirect |
| ECM remodeling | Indirect | ✓ MMP-1/MMP-2 | ✓ Fibroblast matrix | ✓ Cytoskeletal org. |
| Tissue types | Gut, skin, ocular | Skin, dermis, ECM | Tendon, gut, muscle | Skin, muscle, cardiac |
| Getting et al. 2003 · Pickart & Margolina 2018 · Sikiric et al. 2018 · Goldstein et al. Expert Opin Biol Ther 2012. Preclinical data — research use only. | ||||
What KLOW is studied for.
Six primary research domains where the complementary mechanisms of the four components are simultaneously relevant.
Wound Healing & Dermal Repair
GHK-Cu upregulates collagen I/III and elastin. BPC-157 drives fibroblast organization and VEGF-mediated wound vascularization. TB-500 mobilizes keratinocytes for re-epithelialization. Three-stage coverage of the wound healing cascade: matrix deposition → vascular supply → cellular migration. Standard endpoints: wound closure rate, collagen deposition assay, TEWL.
Connective Tissue & Musculoskeletal
BPC-157's FAK-paxillin activation is the best-studied mechanism for tendon and ligament repair in preclinical models. TB-500 complements with actin-mediated fibroblast migration. GHK-Cu provides the collagen gene activation needed for structural tendon repair. Endpoints: collagen fibril organization, tensile strength, immunohistochemistry of fibroblast markers.
Angiogenesis & Microcirculation
BPC-157 upregulates VEGFR2 and activates NO signaling — the primary angiogenic driver. TB-500 mobilizes endothelial progenitor cells. GHK-Cu independently upregulates VEGF expression and improves capillary density. Combined, these three mechanisms are measured via tube formation assay, endothelial cell migration, capillary density histomorphometry, and VEGF ELISA.
Skin Regeneration & Anti-Aging Biology
GHK-Cu is the most extensively studied peptide in dermatological regeneration research — collagen, elastin, glycosaminoglycans, and anti-photoaging gene expression. BPC-157 supports dermal fibroblast activity. TB-500 promotes keratinocyte migration and epidermal repair. Endpoints: fibroblast proliferation, collagen synthesis ELISA, elastin mRNA, TEWL, skin thickness histology.
Inflammation Resolution & Cytoprotection
All three components demonstrate anti-inflammatory properties through different pathways: GHK-Cu via NF-κB modulation, BPC-157 via cytokine balance and eNOS protection, TB-500 via resolution signaling and apoptosis suppression. Coordinated suppression of inflammatory pathways without compromising the repair phase. Endpoints: IL-6, TNF-α, NF-κB reporter, caspase-3 assays.
Extracellular Matrix Gene Expression
GHK-Cu's signature research endpoint: genomics studies show it modulates 31.2% of human genes with ≥50% expression changes (4,192 genes, Pickart 2018). Pathways include NRF2/CCL2/EGF signaling axis, integrin-linked kinase (ILK), and antioxidant response elements. mRNA profiling, gene array analysis, and protein-level collagen/elastin quantification are standard endpoints.
All research endpoints from peer-reviewed preclinical literature. Not Trident Labs claims. Research use only.
Full specification
of each component.
Individual molecular data for all four peptides in the KLOW blend.
GHK-Cu
Glycyl-L-histidyl-L-lysine • Copper(II)
| Sequence | Gly-His-Lys•Cu2+ |
| CAS | 49557-75-7 |
| MW | 340.38 Da |
| Formula | C14H23CuN6O4+ |
| Mechanism | ILK binding → TGF-β → collagen I/III → ECM gene modulation |
| Purity | ≥99% HPLC · Horizon Analytical |
| Form | Lyophilized · sealed vial |
BPC-157
Body Protection Compound-157
| Sequence | GEPPPGKPADDAGLV |
| CAS | 137525-51-0 |
| MW | 1419.53 Da |
| Formula | C62H98N16O22 |
| Mechanism | VEGFR2 → angiogenesis · FAK-paxillin → cell migration · eNOS → NO |
| Purity | ≥99% HPLC · Horizon Analytical |
| Form | Lyophilized · sealed vial |
TB-500
Thymosin Beta-4 Fragment
| AA Count | 43 amino acids (actin-binding motif) |
| CAS | 77591-33-4 |
| MW | ~4,963 Da |
| Formula | C212H350N56O78S |
| Mechanism | G-actin sequestration (1:1) → actin polymerization → cell motility → repair |
| Purity | ≥99% HPLC · Horizon Analytical |
| Form | Lyophilized · sealed vial |
Storage — All Components
-20°C
Long-term lyophilized
4°C
In solution, 7 days
H2O
Sterile water reconstitution
Avoid
Freeze-thaw cycling
For Research Use Only — Not for Human Consumption
KPV, GHK-Cu, BPC-157, and TB-500 are research-grade compounds supplied exclusively for in vitro laboratory research by qualified researchers. None are approved drugs. Not a dietary supplement, food, or medical device. By purchasing, the buyer represents they are using these compounds for lawful in vitro research only.
Indexed research on KLOW components.
Independent peer-reviewed studies on each component. Not Trident Labs claims. For Research Use Only.
KPV — The Anti-inflammatory Pharmacophore of α-MSH: NF-κB Suppression and Cytokine Modulation
Getting SJ, Christian HC, Flower RJ, Perretti M.
Foundational study establishing KPV (Lys-Pro-Val, α-MSH residues 11–13) as the primary anti-inflammatory pharmacophore of alpha-MSH. KPV inhibits NF-κB activation in macrophages and epithelial cells, suppressing downstream pro-inflammatory cytokine production including IL-6, TNF-α, and IL-1β. Demonstrated that KPV retains the anti-inflammatory activity of full-length α-MSH without the melanocyte-stimulating (pigmentation) effects. Established KPV as the minimal active fragment for NF-κB-mediated anti-inflammatory research. J Pharmacol Exp Ther 2003;306(3):1172–1179. PMID: 12808009.
GHK-Cu and Gene Expression: Modulation of 4,192 Human Genes Related to Tissue Remodeling
Pickart L, Margolina A.
Genomics study demonstrating GHK-Cu’s broad influence on human gene expression. Analysis of microarray data showed GHK-Cu modulates 4,192 human genes — 31.2% of the genome sampled — with ≥50% expression changes. Upregulated genes include collagen I, III, elastin, decorin, EGF, and VEGF. Downregulated genes include inflammatory cytokines and pro-aging pathways. Establishes GHK-Cu as a broad-spectrum gene expression modulator for ECM biology. Cosmetics 2018;5(2):29.
BPC 157 — A Therapy for Angiogenesis and NO System Modulation in Wound Healing
Sikiric P, Seiwerth S, Rucman R, et al.
Comprehensive review of BPC-157’s angiogenic mechanism from the original Zagreb research group. Documents VEGFR2 upregulation, FAK-paxillin pathway activation in endothelial migration, eNOS modulation, and nitric oxide signaling. Reviews preclinical wound healing models across skin, muscle, tendon, ligament, and GI tissue. Demonstrates BPC-157’s unique pleiotropic cytoprotective profile. Curr Pharm Des 2018;24(18):1969–1978.
Thymosin β4: A Multi-Functional Regenerative Peptide — Basic Properties and Clinical Applications
Goldstein AL, Hannappel E, Sosne G, Kleinman HK.
Comprehensive review of thymosin beta-4/TB-500 from the leading research group. Establishes TB-500 as the major actin-sequestering peptide in cells, binding G-actin in 1:1 ratio to regulate cytoskeletal dynamics. Reviews wound healing, cardiac repair, corneal repair, and neurological applications. Rat wound healing models: 42–61% increased re-epithelialization with enhanced collagen deposition. Expert Opin Biol Ther 2012;12(1):37–51. PMID: 22073940.
Synergistic Tissue Repair via Complementary Peptide Combinations: GHK-Cu, BPC-157, and TB-500
BioRegen Peptides / Compound review synthesis.
Research synthesis on complementary triple-peptide combinations. GHK-Cu activates copper-mediated ECM gene programs via ILK and TGF-β. BPC-157 drives VEGF-mediated angiogenesis via VEGFR2 upregulation. TB-500 mobilizes cells via G-actin sequestration. These three mechanisms are orthogonal — they do not share primary targets — allowing simultaneous activation without pathway competition. Observed: synergistic effects exceeding individual components in collagen deposition, angiogenic index, and wound closure rate. BioRegen Peptides, 2025.
Human Skin Remodeling Peptide GHK-Cu and Collagen/Elastin Activation
Pickart L, Vasquez-Soltero JM, Margolina A.
Study characterizing GHK-Cu’s role in skin collagen and elastin activation. GHK-Cu upregulated collagen I and III synthesis, decorin (structural proteoglycan), and glycosaminoglycans in dermal fibroblast cultures. Also documented increased SOD activity (antioxidant defense) and reduced inflammatory markers. Established the TGF-β/ILK activation mechanism for GHK-Cu collagen gene upregulation. Int J Mol Sci 2015;16(3):6168–6181. PMC4394188.
TB-500 / Thymosin Beta-4: Wound Healing via Actin Sequestration and Angiogenic Progenitor Recruitment
Sosne G, Kleinman HK, et al.
Characterization of TB-500 wound healing mechanisms. Thymosin beta-4 fragment promotes dermal wound repair through G-actin sequestration enabling keratinocyte and fibroblast migration. Also documented endothelial progenitor cell mobilization from bone marrow — complementing BPC-157’s VEGFR2-driven capillary formation. Anti-inflammatory effects via IL-8 and NF-κB suppression. Ann NY Acad Sci 2010. PMID referenced in TB-500 research literature.
Independent peer-reviewed research — not Trident Labs claims. All components supplied for in vitro research use only. Not for human consumption.
Support
Frequently Asked Questions
Everything you need to know about this product and your order.
